YET another drug fails in erosive hand OA (EHOA). A phase II trial of an IL-1 inhibitor (lutikizumab) vs PBO given to 110 EHOA pts shows not differences in pain outcomes, despite biologic changes in CRP, IL1, neutrophils in those on the IL-1 inhibitor. https://t.co/i2N4vs0Sjb